Hybrigenics, a French biopharma company, announced having successful raised €6.8M ($8M) this summer. The funds will serve to extend their clinical trial for Acute Myeloid Leukemia (AML) to additional European countries. It will also enable the launch of a new phase II clinical study for CML in the United States.
“Thanks to the success of this operation, Hybrigenics takes a new important step towards its goals. This new fundraising will help us reinforce our financial structure and accelerate our international expansion, in order to get important results for our clinical program in the next 24 months” said Remi Delansorne, Hybirgenics’s CEO.
Hybrigenics is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases. Hybrigenics Pharma Inc is the company’s subsidiary in the U.S., and relies on French Tech for most of their operational services.